1. Inhibition of BCR activation by orthogonal inhibitors of SYK-AQL.
Inhibition of BCR activation by orthogonal inhibitors of SYK-AQL. (A and B) Splenic B cells from wild-type (WT) or Syk-AQL mice treated with or without anti‐IgM F(ab′)2 in the absence or presence of 3-MB-PP1 or 1-NM-PP1 (10 μM) for 48 h were examined under a light microscope at original magnification ×40 (A) or original magnification ×100 (B). (C) Western blot analysis with antibodies against phosphotyrosine (pY) of lysates of control and anti-IgM–activated spleen B cells from wild-type (WT) or Syk-AQL mice treated with the indicated concentrations of 1-NM-PP1.
Wen-Horng Wang et al. ImmunoHorizons 2019;3:
Copyright © 2019 The Authors